1. Introduction to Type 1 Diabetes
Type 1 diabetes is a chronic autoimmune disease that poses a significant challenge to medicine and patients worldwide. Understanding its specific characteristics, distinguishing it from other forms of diabetes, and recognizing the underlying mechanisms are crucial for effective diagnosis and treatment.
Definition and Characteristics of an Autoimmune Disease
Type 1 diabetes, formerly known as insulin-dependent diabetes, is an autoimmune disorder.1 In this condition, the body’s immune system, for reasons that remain unclear, mistakenly identifies and destroys healthy beta cells in the pancreas. These cells are responsible for producing insulin, a hormone essential for the proper regulation of blood glucose levels.1 Without sufficient insulin, the body loses its ability to effectively process glucose, leading to elevated blood glucose levels, or hyperglycemia.2 Type 1 diabetes is much less common than type 2 diabetes and usually manifests during childhood or adolescence.4
Key Differences Between Type 1 Diabetes and Other Types
Type 1 diabetes and type 2 diabetes, although both are characterized by hyperglycemia and can lead to serious systemic complications, differ fundamentally in terms of their causes, metabolic mechanisms, and course.3 In type 1 diabetes, an autoimmune reaction that leads to the destruction of pancreatic cells plays a key role.3 In type 2 diabetes, however, the problem is usually insulin resistance, which leads to pancreatic exhaustion as a result of excessive insulin production.3 This fundamental difference in pathophysiology has a direct impact on treatment strategies. In type 1 diabetes, lifelong insulin administration is necessary because the body is unable to produce it.5 In type 2 diabetes, initial treatment often focuses on improving insulin sensitivity or stimulating insulin production. Failure to properly diagnose the type of diabetes can result in inappropriate treatment, delays in initiating insulin therapy, and serious complications, such as diabetic ketoacidosis.6
There are also other, rarer forms of diabetes that must be distinguished from type 1. One example is LADA (Latent Autoimmune Diabetes in Adults), which is essentially a variant of type 1 diabetes. It is characterized by the presence of autoantibodies against pancreatic beta cells, but its symptoms appear later, often between the ages of 40 and 50.2 This indicates that autoimmune diabetes is not limited to childhood. Diagnosing LADA in adults who do not fit the typical profile of type 2 diabetes (e.g., non-obese individuals with rapid disease progression) is extremely important. Autoantibody testing becomes crucial in these cases, as patients with LADA will ultimately require insulin therapy, just as in classic type 1 diabetes.7 It is also worth mentioning monogenic and secondary diabetes, which further broaden the diagnostic spectrum.2
2. Etiology and Risk Factors
The development of type 1 diabetes is a complex process in which genetic predisposition and environmental factors interact, leading to an autoimmune attack on the pancreas.
Genetic Predisposition
The exact causes of type 1 diabetes remain unknown, but genetic predisposition plays a key role.4 This disease is hereditary, and the risk of developing it increases significantly if a close relative has type 1 diabetes—it is estimated that this affects 10 out of 100 people, compared to 3–4 out of 1,000 in the general population.4 Interestingly, the risk of inheriting the condition is higher when the father has type 1 diabetes than when the mother has it.4 It should be emphasized that the progression of the disease is not linked to a single gene; rather, many different genes are involved, including the MHC class II gene, the type 22 tyrosine protein phosphatase gene, and the interleukin-2 alpha receptor gene.4
Environmental Factors
Genetic predisposition alone is not enough to cause type 1 diabetes; environmental factors also play a significant role.4 There is evidence that certain environmental factors may contribute to the development of the disease. These include early infections with certain viruses, such as the Coxsackie virus, the rubella virus, and the mumps virus.4 Other potential factors include feeding infants foods containing gluten, especially before they are 3 months old, which may increase the risk.4 Vitamin D deficiency and an unfavorable gut microbiota composition are also being studied as possible risk factors.4 In addition, a slightly higher risk of developing type 1 diabetes is observed in children born by cesarean section.4 Type 1 diabetes can also develop in people who have other autoimmune diseases.2
The interaction between genetic predisposition and environmental factors suggests a model of disease development in which genetic susceptibility creates the foundation, but an external trigger is necessary to initiate or accelerate autoimmune destruction. This insight is fundamental to research on the prevention of type 1 diabetes. Identifying and modifying these environmental factors—for example, through dietary changes, vaccination against specific viruses, or vitamin D supplementation—could potentially reduce the incidence of the disease in genetically predisposed individuals. Although type 1 diabetes is not currently a preventable disease 9, understanding these mechanisms paves the way for future primary prevention strategies.
The Role of Autoantibodies in Disease Development
In the autoimmune mechanism of type 1 diabetes, the immune system attacks pancreatic cells using specific autoantibodies.4 These autoantibodies are extremely important because they often appear in the blood of patients many years before the onset of any clinical symptoms, signaling the onset of an autoimmune response.4 Key autoantibodies used in the diagnosis, pathological analysis, and prediction of type 1 diabetes include autoantibodies against insulin (IAA), glutamic acid decarboxylase (GADA), IA-2 protein (IA-2A), and zinc transporter 8 (ZnT8A).7 Islet cell autoantibodies (ICA) constitute a broader group of antibodies directed against various islet cell proteins.7
It is important to note that these autoantibodies are not the cause of type 1 diabetes, but rather serve as markers of the body’s destructive immune response directed against its own beta cells.7 Despite their significance, the mechanism by which they are generated in humans remains largely unexplored, although it is believed to be associated with both genetic predisposition and environmental factors.8
The presence of autoantibodies in the blood long before the onset of clinical symptoms—when beta-cell destruction is not yet sufficient to cause overt hyperglycemia—indicates the existence of a prodromal phase. This asymptomatic phase represents a critical window for potential early interventions. The detection of these autoantibodies in high-risk individuals, such as first-degree relatives of patients with type 1 diabetes 7…could enable them to participate in clinical trials. The goal of these trials would be to preserve the remaining beta cells or modulate the immune response before full-blown diabetes develops. This opens up possibilities for strategies to prevent or delay the progression of the disease, shifting the focus from treating an existing condition to proactively modifying its course.
3. Symptoms and Early Signs
Recognizing the symptoms of type 1 diabetes is crucial because they are characterized by a sudden and intense onset, often leading to a life-threatening condition.
Classic symptoms of hyperglycemia in adults and children
The symptoms of type 1 diabetes result directly from elevated blood glucose levels, or hyperglycemia.3 Typical symptoms include increased thirst (polydipsia) and a dry mouth; in children, this can mean drinking anywhere from a few to over a dozen liters of fluids per day.3 This is accompanied by frequent urination (polyuria), including at night.3 Patients often experience an increased appetite (polyphagia) 3; however, unexplained weight loss still occurs.10 General weakness, fatigue, drowsiness, and difficulty concentrating are also common symptoms.3
Severity and progression of symptoms
A characteristic feature of type 1 diabetes is the sudden onset of symptoms, which are very severe and difficult to ignore, often developing over the course of just a few weeks.3 In these cases, blood glucose levels can reach very high values, even as high as 300–400 mg/dl.3 In children, the signs may initially go unnoticed, and clinical symptoms do not appear until only about 20% of the body’s insulin-producing cells remain.11 The speed and severity with which symptoms of type 1 diabetes appear underscore the urgent need for medical intervention. A delay in diagnosis can lead to serious, life-threatening complications, such as diabetic ketoacidosis.6 For this reason, educational campaigns and training for medical personnel are extremely important to ensure the rapid recognition of these classic symptoms and to prevent severe initial manifestations of the disease.
Potential early manifestations and other subtle signs
Sometimes, the first, immediately life-threatening symptom of type 1 diabetes, especially in children, may be diabetic ketoacidosis (DKA).6 Ketoacidosis is often the first manifestation of the disease, resulting from a delayed diagnosis.6
Other symptoms that are often overlooked, especially in children, include:
- Inflammation of the vulvar skin and the area around the foreskin; in infants, diaper rash.11
- White discharge from the genitourinary tract.11
- Mouth ulcers and a general susceptibility to infections.11
- Apathy.11
- Wounds that heal slowly.3
The nonspecific nature of early symptoms in children, combined with the rapid progression of beta-cell destruction, means that ketoacidosis is often the crisis that leads to a diagnosis. This not only poses an immediate threat to the child’s life but also makes the initial diagnosis traumatic for families. This underscores the need for targeted education for parents, teachers, and primary care pediatricians to recognize these subtle signs, which could lead to earlier detection and prevention of ketoacidosis as the first manifestation of type 1 diabetes.
4. Diagnosis of Type 1 Diabetes
Accurate diagnosis of type 1 diabetes is based on the assessment of blood glucose levels and the detection of specific autoantibodies, which allows for precise determination of the type of disease and the implementation of appropriate treatment.
Diagnostic criteria (fasting blood glucose, OGTT, HbA1c)
A diagnosis of diabetes is made when at least one of the following criteria is met 12:
- Fasting blood glucose: Plasma glucose concentration of ≥7.0 mmol/l (126 mg/dl)—confirmed twice on different days.12 This test should be performed after fasting for at least 8 hours.13
- Random blood glucose: A plasma glucose concentration of ≥11.1 mmol/l (200 mg/dl) at any time of day (not necessarily on an empty stomach), accompanied by typical symptoms of hyperglycemia, such as thirst, polyuria, or weakness. In type 1 diabetes, diabetic ketoacidosis may also be present.12
- Blood glucose level 2 hours after an oral glucose tolerance test (OGTT): A plasma glucose concentration of ≥11.1 mmol/l (200 mg/dl).12 The OGTT is typically performed when fasting blood glucose is within the range of 5.6–6.9 mmol/l (100–125 mg/dl).12
- Glycated hemoglobin (HbA1c): A value of ≥6.5% (48 mmol/mol), measured in a laboratory using methods certified by the NGSP.12
Screening using HbA1c, fasting glucose, or a 2-hour OGTT is recommended for individuals at high risk for diabetes.13 If the results are below the diagnostic thresholds (HbA1c <5.7%, fasting glucose <5.6 mmol/l, 2-hour OGTT <7.8 mmol/l), testing should be repeated every 3 years.13 It should be noted that HbA1c measurements may yield false-negative results in individuals with conditions affecting the function or number of red blood cells; in such cases, measuring glucose in venous blood is essential.13
The table below summarizes the diagnostic criteria for type 1 diabetes:
Table 1: Diagnostic Criteria for Diabetes
| Criterion | Threshold value for diagnosing diabetes (plasma glucose) | Additional notes |
| :— | :— |:— | :— | | Fasting blood glucose | ≥7.0 mmol/l (126 mg/dl) | Twice (on different days); after fasting for at least 8 hours | | Random blood glucose | ≥11.1 mmol/l (200 mg/dl) | With typical symptoms of hyperglycemia (thirst, polyuria, weakness); possible diabetic ketoacidosis in T1D | | 2-hour OGTT | ≥11.1 mmol/l (200 mg/dl) | Performed if fasting blood glucose is 5.6–6.9 mmol/l (100–125 mg/dl) | | HbA1c | ≥6.5% (48 mmol/mol) | Determined in the laboratory using NGSP-certified methods; false-negative results are possible in cases of RBC disorders |
Laboratory Tests for Autoantibodies and Their Significance
Autoantibodies against pancreatic islet cells are crucial in the diagnosis of type 1 diabetes, as they serve as markers of the body’s destructive immune response against its own beta cells.7 Their presence indicates the onset of an autoimmune process.4
The most important autoantibodies used in the diagnosis, pathological analysis, and prediction of type 1 diabetes include the following 7:
- Insulin autoantibodies (IAA): These are often the first marker to appear in young children at risk for diabetes.7 An IAA test should be performed before starting insulin therapy.7
- Autoantibodies against glutamic acid decarboxylase (GADA): These may also be detected in patients without diabetes who have other autoimmune diseases.7
- Autoantibodies against IA-2 protein (IA-2A): These serve as surrogate markers for pancreatic beta-cell destruction.8
- Autoantibodies against zinc transporter 8 (ZnT8A): Like IA-2A, they serve as surrogate markers for pancreatic beta-cell destruction.8
- Islet cell cytoplasmic autoantibodies (ICA): These measure a group of autoantibodies directed against various islet cell proteins.7
At the time of the initial diagnosis of type 1 diabetes, one or more of these autoantibodies are present in approximately 95% of patients.7 Their presence in a person with symptoms of diabetes strongly supports a diagnosis of type 1 diabetes.7 Testing for the GADA/IA-2A combination is often more cost-effective.7 It should be noted that islet autoantibodies may also be present in patients with other autoimmune endocrine disorders.7
The table below lists the key autoantibodies in the diagnosis of type 1 diabetes:
Table 2: Key Autoantibodies in the Diagnosis of Type 1 Diabetes
| Name: Autoantibodies | Significance in Diagnostics/Pathophysiology | Notes |
| IAA (Anti-insulin autoantibodies) | Often the first marker in young children at risk for diabetes; an autoimmune marker | Test before starting insulin therapy |
| GADA (Autoantibodies against glutamic acid decarboxylase) | Autoimmune marker | May be present in other autoimmune diseases |
| IA-2A (Autoantibodies against the IA-2 protein) | Marker of pancreatic beta cell destruction | Often tested in combination with GADA for cost-effectiveness |
| ZnT8A (Autoantibodies against zinc transporter 8) | Marker of pancreatic beta cell destruction | |
| ICA (Cytoplasmic autoantibodies against pancreatic islet cells) | A group of autoantibodies against various islet cell proteins | A semi-quantitative test; requires experience in interpretation |
The diagnosis of type 1 diabetes is based on two pillars: confirmation of hyperglycemia and identification of the autoimmune basis of the disease. While glycemic criteria (fasting glucose, OGTT, HbA1c) confirm the presence of diabetes, it is the presence of autoantibodies that confirms its autoimmune nature. This dual approach is essential for proper patient management. A diagnosis based solely on hyperglycemia could lead to misclassification (e.g., as type 2 diabetes), resulting in inappropriate treatment strategies, such as attempts to treat with oral medications instead of immediate insulin therapy. Confirmation of the autoimmune etiology ensures that patients receive appropriate, lifelong insulin therapy from the very beginning 5 and allows for monitoring for other coexisting autoimmune diseases.2 This is also relevant to genetic counseling and family screening.4
Furthermore, the presence of autoantibodies many years before the onset of clinical symptoms, indicating an ongoing autoimmune response 4, has predictive value. For example, among first-degree relatives of patients with type 1 diabetes who have been found to have ICA and a low insulin response to an intravenous glucose infusion, the 5-year risk of developing type 1 diabetes is approximately 60%.7 This predictive capability opens up opportunities for presymptomatic diagnosis and potential early interventions. Identifying high-risk individuals through screening for autoantibodies could enable their participation in clinical trials aimed at immunomodulation, with the goal of preventing or delaying beta-cell destruction before overt clinical symptoms appear.14 This represents a paradigm shift from reactive disease management to proactive modification of the disease course. Ethical and practical issues related to screening asymptomatic individuals, as well as the availability of effective and safe interventions, remain a challenge.
5. Treatment and Management of Type 1 Diabetes
The treatment of Type 1 diabetes involves a comprehensive approach centered on insulin therapy, supplemented by precise glucose monitoring, an appropriate diet, and regular physical activity.
Insulin Therapy—The Primary Treatment
Treatment of type 1 diabetes involves lifelong exogenous insulin administration to compensate for the body’s lack of insulin.5
Types of Insulin and Their Action Profiles
Currently, both human insulins, produced using recombinant DNA technology, and insulin analogs, which have a more predictable action profile, are used.16
- Human insulins:
- Short-acting insulins (e.g., Actrapid, Humulin R, Polhumin R, Gensulin R) are characterized by an onset of action after about 30 minutes, a peak after 1–3 hours, and a total duration of action of 6–8 hours. They are administered with meals.16
- Intermediate-acting insulins (e.g., Insulatard, Humulin N, Gensulin N, Polhumin N) begin to take effect after about 1.5 hours, reach their peak after 3–10 hours, and remain active for 10–16 hours. They are used as basal insulin, typically twice daily.16
- Ready-to-use mixtures of human insulins are also available, containing a specific percentage of short-acting and intermediate-acting insulin (e.g., Mixtard 30, Gensulin M30, Polhumin Mix 3).16
- Insulin analogs:
- Rapid-acting insulins (e.g., Humalog, NovoRapid, Apidra) have a very rapid onset of action (5–15 minutes), peak after 1–2 hours, and a duration of action of 4–6 hours.16 The ultra-rapid-acting insulin Fiasp begins to work in as little as 2 minutes and can even be administered after a meal.16 Their use reduces the risk of postprandial hypoglycemia but requires insulin to be administered with every meal, including snacks.16
- Long-acting insulins (e.g., Levemir, Lantus, Abasaglar, Toujeo, Tresiba) are characterized by a stable, prolonged, and non-peaking action profile. They reach full effect after about 2 hours, and their duration of action is 20–24 hours (Tresiba up to 42 hours).16 This action profile potentially reduces the risk of hypoglycemia, especially at night, and improves quality of life.16
- Analog mixtures are also available (e.g., NovoMix 30, Humalog Mix 25).16
The table below provides an overview of the types of insulin and their action profiles:
Table 3: Types of Insulin and Their Action Profiles
| Insulin Category | Examples of Preparations | Onset of Action | Peak Effect | Duration of Action |
| Rapid-acting analogs | Apidra, Humalog, NovoRapid, Fiasp | 5–15 min (Fiasp after 2 min) | 1–2 hours | 4–6 hours (Fiasp: 4–5 hours) |
| Short-acting human insulins | Actrapid, Humulin R, Gensulin R, Polhumin R | 30 min | 1–3 hours | 6–8 hours |
| Intermediate-acting human insulins | Gensulin N, Humulin N, Insulatard, Polhumin N | 1.5 hours | 3–10 hours | 10–16 hours |
| Long-acting analogs | Abasaglar, Lantus, Levemir, Toujeo | 2 hours until full effect | No peak | 20–24 hours |
| Ultra-long-acting analogs | Tresiba | 2 hours until full effect | No peak | 24–42 hours |
| Human insulin mixtures | Gensulin M, Humulin M, Mixtard, Polhumin Mix | 30–45 min | 2–3/4–8 hours | 10–16 hours |
| Analog mixtures | Humalog Mix, NovoMix | 15 min | 1–2/4–8 hours | 10–16 hours |
Methods of Insulin Administration
Insulin is administered using various methods that have evolved to improve the comfort and precision of treatment.
- Insulin pens: These are handy, pen-sized devices that have largely replaced traditional syringes. Thanks to their very short and thin needles, injections are nearly painless and easy to administer as part of daily routines.18
- Insulin pumps (CSII—continuous subcutaneous insulin infusion): These are small devices that can be attached to the body, such as to a belt. They are connected to a thin cannula placed under the skin, usually on the abdomen, and deliver insulin directly into the subcutaneous fat through a tube.18 Pumps eliminate the need for repeated manual injections and allow for more flexible insulin delivery.18 They deliver small amounts of rapid-acting insulin evenly throughout the day (known as the basal rate) and allow for bolus doses with meals, based on the grams of carbohydrates consumed and the current glucose level.18 An increasing number of people with type 1 diabetes, especially children and adolescents, are using insulin pumps.18 There are two types of pumps: drainage pumps (with a tube) and non-drainage pumps (patch-type), which are attached directly to the skin and controlled by a remote.18 Insulin pump therapy is more expensive and requires prior approval from health insurance providers.18 Patient education programs are also required.18
The most advanced form of insulin therapy for type 1 diabetes is the advanced closed-loop system (AHCL). It consists of an insulin pump connected to a continuous glucose monitor (CGM).18 An algorithm in the pump or smartphone app automatically adjusts basal insulin to maintain blood glucose within the target range, although the amount of carbohydrates per meal must still be entered manually to deliver bolus insulin.19
The evolution from traditional insulin pens to insulin pumps and continuous glucose monitoring systems, and then to hybrid closed-loop systems, reflects a clear technological trend. This progress is not merely about convenience, but above all about increasingly precisely mimicking the natural, dynamic insulin secretion of a healthy pancreas. Pumps deliver basal insulin continuously and boluses with meals, while closed-loop systems automatically adjust basal insulin based on real-time blood glucose data. This technological advancement significantly improves glycemic control, which translates to fewer complications, better quality of life, and longer life expectancy for patients with type 1 diabetes.20 This shifts diabetes management beyond simple insulin replacement toward a more sophisticated, adaptive strategy, reducing the burden associated with constant manual adjustments and minimizing the risk of both hypoglycemia and hyperglycemia. This trend points to a future in which type 1 diabetes management will become increasingly automated and personalized, freeing patients from some of the daily complexities associated with their condition.
Glucose Monitoring
Regular monitoring of blood glucose levels is essential for effectively adjusting insulin doses and dietary plans.5
- Self-monitoring of blood glucose (SMBG): A traditional method of measuring blood glucose that provides information about glucose levels at a given moment.19
- Continuous glucose monitoring (CGM, iCGM): Enables continuous tracking of glucose levels, providing a more complete picture of trends and helping to detect both drops and spikes that might be missed with occasional measurements.18
The Role of Diet and Physical Activity
Diet and physical activity are integral components of comprehensive treatment for type 1 diabetes, complementing insulin therapy.
- Diet: A proper diet, rich in nutrients and low in processed sugars and fats, is essential.5 It is recommended to eat meals regularly, at set times, and to limit sweets, high-glycemic-index carbohydrates, and saturated fats.9 It is also important to pay attention to the quality of the meals you eat, which should be rich in vegetables and seeds that provide vitamins and minerals. It is also recommended to drink about 2 liters of still water per day.9
- Physical activity: It is a cornerstone of diabetes treatment.21 Regular exercise helps control blood glucose levels and increase tissue sensitivity to insulin.5 It can also contribute to weight loss.21 Regular physical activity, performed 4–5 times a week for at least 45 minutes, can “take the place” of insulin in lowering blood glucose levels, which may allow for slightly lower doses of medication.21
- It is extremely important to prepare properly for physical activity, taking into account one’s health status, fitness level, and type of treatment, as the risk of hypoglycemia is highest with insulin therapy.21
- It is recommended to engage in physical activity approximately 3 hours after administering short-acting insulin to minimize the risk of hypoglycemia, as exercise enhances the drug’s effect.21
- Aerobic exercise, such as walking, long-distance running, cycling, yoga, or team sports, effectively lowers blood sugar levels.21
Detailed guidelines on physical activity for people with type 1 diabetes highlight the complexity of integrating lifestyle factors into disease management. Although exercise is highly beneficial, it poses unique challenges for insulin-dependent individuals due to the risk of hypoglycemia. This requires precise knowledge and careful planning, which underscores the need for individualized exercise plans developed in consultation with healthcare providers. It also underscores the importance of continuous glucose monitoring during physical activity to effectively and safely manage fluctuations in glucose levels.
Patient education and self-management
Patient education on self-management of the disease is extremely important.5 The treatment of type 1 diabetes requires a comprehensive approach that includes both medication and lifestyle changes, with the treatment plan tailored to each patient’s individual needs.5 Modern tools and mobile apps are indispensable aids in diabetes management, as they facilitate health monitoring, meal planning, medication reminders, and maintaining physical activity.5
Despite technological advances, managing type 1 diabetes remains a highly active and informed process for the patient. Technology is a powerful tool, but it does not replace the patient’s understanding of their own body, the disease, and the complex interactions between insulin, food, and physical activity. Effective care for people with type 1 diabetes is based on a partnership in which comprehensive patient education enables them to interpret data, make informed decisions, and actively participate in their own care—all of which are crucial for achieving optimal glycemic control and preventing long-term complications. This suggests that access to high-quality education and support resources is just as important as access to technology.22
6. Complications of Type 1 Diabetes and Their Prevention
Type 1 diabetes, if not properly controlled, can lead to a number of serious complications—both acute and chronic—that threaten the patient’s health and life.
Acute Complications
Acute complications of Type 1 diabetes develop rapidly and require immediate medical intervention.
Hypoglycemia (low blood sugar)
Hypoglycemia is a decrease in blood glucose levels below 70 mg/dl (3.9 mmol/l), with clinically significant hypoglycemia occurring at glucose levels below 54 mg/dl (3.0 mmol/l).6 It is the most common acute complication of diabetes.6 Symptoms include pallor, anxiety, irritability, sweating, drowsiness, seizures, and, in extreme cases, loss of consciousness.6 The rate at which symptoms develop depends on how rapidly blood glucose levels drop.6 The most common causes of hypoglycemia are administering too high a dose of insulin or insufficient carbohydrate intake with a meal.6 In people who have had the condition for a long time, so-called “unrecognized hypoglycemia” may occur, in which warning symptoms are diminished or absent.6
Diabetic Ketoacidosis (DKA)
Diabetic ketoacidosis is often the first manifestation of type 1 diabetes, which usually indicates a delayed diagnosis of the disease.6 It always develops when insulin stops reaching the body, for example, due to a blockage in the insulin pump’s infusion set or a missed insulin injection.6 This complication develops within a few hours, and its characteristic feature is the presence of ketone bodies in the urine and blood, accompanied by hyperglycemia.6 The most common causes are infections, discontinuation of insulin therapy, or an insufficient insulin dose.6 Symptoms include excessive thirst, dry mouth, polyuria, nausea, and vomiting, abdominal pain, heavy, deep, and rapid breathing (Kussmaul breathing), altered consciousness, weakness, and a characteristic acetone odor on the breath.6 Ketoacidosis, which presents with muscle rigidity, vomiting, and diarrhea, can mimic acute abdominal pain.6 To diagnose ketosis, every person with type 1 diabetes should have urine or blood ketone test strips on hand.6
The fact that diabetic ketoacidosis is often the first manifestation of type 1 diabetes and usually results from a delayed diagnosis highlights the critical need to raise public awareness of the symptoms of type 1 diabetes, especially among parents and primary care physicians. Early recognition and diagnosis can prevent severe episodes of ketoacidosis, which are not only dangerous for the patient but also costly for the healthcare system. Enabling patients to monitor ketones at home using test strips is a direct intervention stemming from this insight, allowing for the early detection of ketosis and the potential prevention of full-blown ketoacidosis.
Chronic complications
Chronic complications of diabetes develop as a result of long-term, untreated, or poorly controlled hyperglycemia.6 They can affect many systems of the body.
- Atherosclerosis: Diabetes is an independent risk factor for the development of atherosclerosis.6
- Diabetic kidney disease (diabetic nephropathy): This is functional and structural damage to the kidneys caused by chronic hyperglycemia.6 Its development depends on the duration of diabetes, the degree of glycemic control, concomitant hypertension, and genetic factors.6 Initially, the disease is asymptomatic and can only be detected through a urine test, which reveals excessive albumin excretion (albumin-to-creatinine ratio—ACR).6 Symptoms such as general weakness, easy fatigability, edema, high blood pressure, and a grayish-pale skin color do not appear until the advanced stage.6 Diabetic nephropathy is the most common cause of end-stage renal failure and the need for chronic dialysis.6
- Diabetic eye disease (diabetic retinopathy): In the early stages of type 1 diabetes, retinopathy occurs sporadically (in about 2% of patients), but after 15 years, it is found in as many as 98% of patients.6 It can lead to permanent vision loss.9
- Diabetic neuropathy: Nerve damage that can lead to a loss of sensation, including touch, pain, and temperature perception.9
- Diabetic foot syndrome: Damage to nerves and blood vessels results in wounds that are difficult to heal; in extreme cases, amputation may be necessary.6
- Other: Chronic complications may also include skin, joint, and bone changes.6 Untreated diabetes can lead to damage to the brain and heart and cause impotence.9
The dual nature of complications—acute crises versus insidious, chronic damage—underscores the need for a comprehensive and ongoing approach to managing type 1 diabetes. It is not just a matter of preventing immediate crises (which require a rapid response and patient education on symptoms and ketone testing), but also of careful, long-term glycemic control and regular screening (e.g., annual ACR 6 testing) to detect and manage insidious, chronic damage before it becomes irreversible. This means that patient education must cover both the management of acute crises and the importance of long-term adherence to recommendations in order to prevent chronic complications that significantly impact quality of life and life expectancy.
Strategies for the Prevention and Early Detection of Complications
Maintaining optimal glycemic control is key to preventing complications of type 1 diabetes. The better the glycemic control, the fewer complications there are, and consequently, the better the quality of life and the longer the life expectancy of patients.20
Prevention strategies include:
- Regular medical checkups and health monitoring: These help detect and treat complications at an early stage.5
- Renal monitoring: Measurement of urinary albumin (ACR) once a year in adults with diabetes. If the eGFR is below 60 mL/min/1.73 m² and/or the ACR is above 30 mg/g, the test should be repeated every 6 months.6
- Regular blood glucose monitoring: This is essential for ongoing disease management.2
- Lifestyle changes:
- Physical activity: Choosing the right type of exercise is important for overall health and blood sugar control.9
- Diet: Eat meals regularly at set times, and limit sweets, high-glycemic-index carbohydrates, and saturated fats. The diet should be rich in vegetables and seeds, which provide vitamins and minerals. It is also recommended to drink about 2 liters of still water per day.9 In cases of diabetic nephropathy, it is recommended to limit protein intake.6
- Weight Management: Maintaining a healthy body weight through a balanced diet and regular physical activity is crucial for improving metabolic control and reducing the risk of complications.5
- Avoiding substances toxic to the kidneys: This is particularly important for patients with diabetic nephropathy.6
- Quitting smoking: Smoking increases the risk of developing diabetes and its complications.2
Although insulin is absolutely essential in type 1 diabetes 5, lifestyle factors such as physical activity, a balanced diet, and weight management play a significant role in modulating the progression of the disease and preventing complications.6 This goes beyond the simplistic belief that it is enough to “just take insulin.” Instead, it emphasizes that managing type 1 diabetes is a holistic process, requiring patients to actively engage in healthy behaviors to support overall metabolic health, reduce the risk of cardiovascular 6, and potentially reducing the severity or delaying the onset of microvascular complications, which in turn improves long-term health outcomes and quality of life.
7. Recent Research and Future Therapies
Current scientific research on type 1 diabetes focuses on innovative approaches that go beyond traditional disease management, aiming for a potential cure and more physiological treatment methods.
Advances in Immunotherapy
Type 1 diabetes, due to its autoimmune nature, has become one of the primary targets of cell therapy.15 Research on beta-cell transplantation without the need for immunosuppression represents a breakthrough in the treatment of type 1 diabetes.14 This paves the way for eliminating the need for daily insulin and immunosuppressive medications, which would be a significant change in patients’ lives, provided the efficacy and safety of this method are confirmed in subsequent phases of research.14
Beta Cell Regeneration and Transplants
Currently, the derivation of differentiated pancreatic islet beta cells in vitro remains at the research stage.15 However, numerous studies indicate that in the future it will be possible to obtain insulin-producing beta cells that are sensitive to blood glucose levels, which can be transplanted into patients with type 1 diabetes.15 The success of this therapy depends on developing safe protocols for obtaining beta cells and ensuring that the transplanted cells do not trigger an immune response in the recipient and retain their biological functions.15
There have been promising reports of a breakthrough therapy using genetically modified insulin-producing cells, developed by the American company Sana Biotech. In the first person to participate in the study, trace levels of insulin were observed in the blood after 28 days of therapy, whereas the body had previously produced no insulin at all. These cells survived and continued to produce insulin for 12 weeks. As a result, clinical trials are scheduled for 2026.24 In addition, reports of a patient who, 35 years later, is once again producing insulin following a beta-cell transplant without immunosuppression, reinforce hopes for a one-time, functional cure for type 1 diabetes.14 Stem cell therapy is also mentioned as a potential lifeline for patients with type 1 diabetes.14
Current treatment for type 1 diabetes focuses on lifelong insulin replacement and meticulous disease management.5 However, this groundbreaking research on genetically modified insulin-producing cells, beta-cell transplants without immunosuppression, and stem cell therapy points to a fundamental paradigm shift in the treatment of type 1 diabetes. They shift the focus from merely managing the symptoms of insulin deficiency to actively restoring the body’s ability to produce insulin. This offers tremendous hope for a functional cure or long-term remission, which would significantly improve the quality of life for millions of patients by eliminating the daily burden of injections and constant monitoring, and would also significantly reduce the risk of long-term complications. Ensuring the safety, efficacy, and scalability of these advanced therapies remains a challenge.
The Development of an Artificial Pancreas and Smart Insulin
Alongside research into cell therapy, artificial pancreas technology is advancing rapidly. The artificial pancreas, or Automated Hybrid Closed Loop (AHCL) system, is considered the future of type 1 diabetes treatment.20 This system, which combines an insulin pump with a continuous glucose monitor (CGM), significantly improves glycemic control compared to conventional methods.18 Better glycemic control directly translates to fewer complications, improved quality of life, and longer life expectancy for patients with type 1 diabetes.20 The artificial pancreas is one of the research initiatives that are expected to become the standard of care for type 1 diabetes in a few to several years.20
The development of the artificial pancreas represents a key “bridge technology.” It utilizes existing insulin delivery and monitoring systems (pumps, CGM) along with advanced algorithms to provide more automated and effective glycemic control right now, while more radical biological solutions are still in advanced stages of research and clinical trials. This two-pronged approach ensures that patients benefit from continuous improvements in disease management while awaiting potential curative therapies, underscoring the ongoing commitment to improving the lives of people with type 1 diabetes.
8. Support for People with Type 1 Diabetes
Living with type 1 diabetes is a daily challenge, which is why access to comprehensive support—both from patient organizations and online communities—is crucial.
Patient Organizations and Associations
There are numerous organizations in Poland and around the world whose mission is to support people with type 1 diabetes and their families.
- Polish Diabetes Association: Its mission is to provide diabetes education to patients and their families, foster a sense of community among people with diabetes, work to improve treatment conditions, and raise public awareness of diabetes.23 The Association has a Central Board and can be reached using the contact information provided.23
- The Foundation for Children with Diabetes: It has prepared a free guide titled “Diagnosis… What Now?”22 This guide is designed to help parents of children with newly diagnosed type 1 diabetes navigate their new reality and find support during this difficult time.22
Online Guides and Forums
The Internet has become an important source of information and support for people with diabetes.
- The guide “Diagnosis… What Now?”: This is a dedicated resource for parents of children with newly diagnosed type 1 diabetes, designed to help them through the difficult period following the diagnosis.22
- The mojacukrzyca.org website: This is a popular and highly recommended website among people with diabetes; it has been operating for 16 years and provides reliable information about diabetes every day.25
- Diabetes UK Support Forum: This is an international online community where people with diabetes (of all types), their families, and caregivers can share knowledge and experiences. The forum is free and easy to use.26
The Importance of Psychological Support
A diagnosis of diabetes, especially type 1, is often overwhelming, and patients and their families actively seek support.22 Although psychological support is not explicitly listed as a separate item in the available information, it is an integral part of comprehensive care. This stems from the need to “find one’s place in the new reality of living with diabetes” 22 and to cope with a chronic condition that requires ongoing management and adaptation.
The presence and importance of patient organizations and online communities underscore that effective management of type 1 diabetes—a chronic, complex, and lifelong condition—goes far beyond medical interventions. Psychological, social, and practical support from peers and dedicated organizations is crucial for empowering patients and their families to cope with daily challenges, reduce feelings of isolation, sharing best practices, and maintaining motivation for self-management of the disease. This underscores the holistic nature of care, where community support serves as an essential complement to medical treatment, significantly impacting the patient’s quality of life and adherence to treatment recommendations.
In addition, targeted support, such as the guide “Diagnosis… What Now?” for parents of children with newly diagnosed type 1 diabetes 22, is extremely important. This particular focus on new diagnoses and pediatric patients highlights the identification of specific, stressful transition points in the course of the disease. Effective support programs are not one-size-fits-all, but are often tailored to the specific needs and critical moments in the life of a patient with diabetes. The initial diagnosis, especially in children, is a deeply overwhelming experience 22, requiring immediate practical and emotional support. Providing targeted resources at such times can significantly improve initial coping mechanisms, facilitate faster adaptation to a new reality, and create a stronger foundation for long-term self-management, potentially reducing the likelihood of early burnout or poor treatment compliance.
Summary
Type 1 diabetes is a complex autoimmune disease characterized by the destruction of pancreatic beta cells and the absolute necessity of lifelong insulin therapy. Distinguishing it from other types of diabetes, particularly type 2 diabetes and LADA, is fundamental to proper treatment, which underscores the importance of a diagnostic approach based on both glycemic criteria and autoantibody testing. The presence of autoantibodies long before the onset of clinical symptoms opens up possibilities for early intervention and the potential to delay disease progression.
Managing type 1 diabetes is a holistic process that involves not only precise insulin therapy using advanced technologies, such as insulin pumps and continuous glucose monitors, but also strict adherence to dietary recommendations and regular physical activity. Although insulin is essential, lifestyle factors play a key role in improving metabolic control and preventing complications.
This disease is associated with the risk of both acute complications, such as hypoglycemia and diabetic ketoacidosis, and chronic complications, which can lead to serious organ damage. Effective blood glucose control and regular screening are key to minimizing this risk.
The future of type 1 diabetes treatment looks promising, with intensive research into cell therapies, beta cell regeneration, and the development of an artificial pancreas. These innovations aim to restore natural insulin production or significantly automate disease management, which would represent a breakthrough in patients’ quality of life.
Finally, support for patients and their families is of crucial importance. Patient organizations, guides, and online forums play an irreplaceable role in education, integration, and psychological support, helping people with type 1 diabetes cope with daily challenges and live life to the fullest.
Cited works
- Types of Diabetes – Polish Diabetes Association, accessed August 19, 2025, https://diabetyk.org.pl/typy-cukrzycy/
- Causes of Diabetes – What Can Cause It? | DANN, accessed August 19, 2025, https://www.dann.edu.pl/artykuly/jakie-sa-przyczyny-cukrzycy.html
- Type 1 and Type 2 Diabetes – Symptoms, Treatment, Differences | Synexus – Home Page, accessed August 19, 2025, https://www.przychodniasynexus.pl/cukrzyca-typu-1-i-2-czym-sie-roznia-jak-wyglada-leczenie-obu-schorzen/
- Is there a risk of developing type 1 diabetes? – diabinfo, accessed August 19, 2025, https://www.diabinfo.de/pl/zapobieganie-cukrzycy/cukrzyca/czy-jestem-zagrozony/czy-istnieje-ryzyko-wystapienia-cukrzycy-typu-1.html
- Diabetes—Types, Symptoms, Treatment, Diet—Prokocim Medical Center, accessed August 19, 2025, https://cmprokocim.pl/jednostki-chorobowe/cukrzyca/
- Complications of Type 1 Diabetes, accessed August 19, 2025, https://bezcukrzycy.com/powiklania-w-cukrzycy-typu-1/
- Diabetes-related autoantibodies | Pathology Tests Explained, accessed August 19, 2025, https://pathologytestsexplained.org.au/ptests.php?q=Diabetes-related%20autoantibodies
- Anti-Islet Autoantibodies in Type 1 Diabetes – PMC – PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10298549/
- Diabetes – How to Prevent It – Pacjent.gov, accessed August 19, 2025, http://pacjent.gov.pl/aktualnosc/cukrzyca-jak-jej-zapobiec
- Type 1 Diabetes – Description, Symptoms, Treatment | Ziko Pharmacy – e-ZikoApteka, accessed: August 19, 2025, https://www.e-zikoapteka.pl/encyklopedia/choroby/cukrzyca-typu-1
- Diabetes in Children—Most Common Symptoms. How to Support Your Child?—Zwrotnik Raka, accessed August 19, 2025, https://www.zwrotnikraka.pl/cukrzyca-u-dzieci/
- Table 13.1-2. WHO Criteria for the Diagnosis of Diabetes | Internal Medicine – Practical Medicine, accessed August 19, 2025, https://www.mp.pl/interna/table/016_9564
- ADA Recommendations – Laboratory Tests for Patients with Diabetes – Termedia, accessed August 19, 2025, https://www.termedia.pl/diabetologia/Rekomendacje-ADA-badania-laboratoryjne-u-chorych-na-cukrzyce,52602.html
- A breakthrough in the treatment of type 1 diabetes. After 35 years, a patient is producing insulin again. Published: August 19, 2025, https://aptekarski.com/artykul/przelom-w-leczeniu-cukrzycy-typu-1-pacjent-po-35-latach-znow-produkuje-insuline
- Cell Therapy for Type 1 Diabetes—Will It Be Possible? – Via Medica Journals, accessed August 19, 2025, https://journals.viamedica.pl/clinical_diabetology/article/download/8414/7175
- Types of insulin. Which insulin should you choose? How do insulins work? – Cukrzyca.pl, accessed August 19, 2025, https://cukrzyca.pl/cukrzyca/rodzaje-insulin/
- Types of insulin – Polish Diabetes Association, accessed August 19, 2025, https://diabetyk.org.pl/rodzaje-insulin/
- Insulin Therapy: What Assistive Devices Are Available? – diabinfo, accessed August 19, 2025, https://www.diabinfo.de/pl/zycie-z-cukrzyca/leczenie/technika-terapeutyczna.html
- Understanding Diabetes Technology – DigiBete, accessed August 19, 2025, http://www.digibete.org/wp-content/uploads/2024/01/MakingSenseofTechnology-POLISH_0501.pdf
- The Artificial Pancreas—The Future of Type 1 Diabetes Treatment – Diabetology – Termedia, accessed August 19, 2025, https://www.termedia.pl/diabetologia/Sztuczna-trzustka-przyszlosc-leczenia-cukrzycy-typu-1,49013.html
- Physical Activity – A Cornerstone of Diabetes Treatment – Polish Diabetes Association, accessed August 19, 2025, https://diabetyk.org.pl/aktywnosc-fizyczna-filar-leczenia-cukrzycy/
- Diagnosis… and what next? – Polish Diabetes Association, accessed August 19, 2025, https://diabetyk.org.pl/diagnoza-i-co-dalej/
- Polish Diabetes Association – Everything About Diabetes, accessed August 19, 2025, https://diabetyk.org.pl/
- Type 1 diabetes without injections. A breakthrough treatment – Polish Diabetes Association, accessed August 19, 2025, https://diabetyk.org.pl/cukrzyca-typu-1-bez-zastrzykow-przelomowa-terapia/
- Online Support – Living with Diabetes – Mediaplanet, accessed August 19, 2025, https://www.jakzyczcukrzyca.pl/zycie-z-choroba/wsparcie-z-sieci/
- Diabetes Support Forum, accessed August 19, 2025, https://www.diabetes.org.uk/support-for-you/community-support-and-forums/online-support-forum
How useful was this post?
Click on a star to rate it!
Average rating / 5. Vote count:
No votes so far! Be the first to rate this post.







